Optimizing CLL Care: Navigating Treatment Modifications and Managing Adverse Events
The discussion, led by Kirollos Hanna,PharmD, BCPS, BCOP, FACCC, and Brandon Dyson, PharmD, BCOP, BCPS, focuses on optimizing chronic lymphocytic leukemia care through the management of treatment modifications and adverse events, emphasizing pharmacists’ roles in patient education, dose adjustment strategies, and the economic impact of these modifications.
EP. 1: BTK Inhibitor-Associated Adverse Events
September 16th 2024The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.
Watch
EP. 2: Managing Adverse Events and Supportive Care Measures in CLL Treatment
September 16th 2024The discussion covers proactive strategies and interventions for managing adverse events before dose modification and explores supportive care measures for chronic lymphocytic leukemia treatments, including variations based on specific Bruton tyrosine kinase inhibitors.
Watch
